AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Inclusion Criteria

• •Criteria:
• •AST/ALT =\< 2.5 times upper limit of normal
• •Creatinine normal OR creatinine clearance \>= 60 mL/min
• •Measurable contrast-enhancing tumor \>= 1 cm in longest diameter by baseline MRI or CT scan:
• •* Patient must have been on no steroids OR a stable dose of steroids for \>= 5 days prior to baseline MRI or CT scan
• •* Patients who are on steroids must be maintained on a stable corticosteroid regimen from baseline scan until the start of study treatment
• •No intratumoral or peritumoral hemorrhage by MRI
• •Karnofsky performance status \>= 60%
• •No other concurrent malignancy within the past 5 years except curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
• •Mini-mental status examination score \>= 15
• •Histologically confirmed glioblastoma multiforme
• •Platelet count \>= 100,000/mm3
• •Hemoglobin \>= 8 g/dL
• •Bilirubin normal
• •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD2171
• •Mean QTc =\< 470 msec (with Bazett's correction) on screening electrocardiogram
• •No history of familial long QT syndrome
• •No greater than +1 proteinuria on 2 consecutive dipsticks taken \>= 1 week apart unless first urinalysis shows no protein
• •No uncontrolled intercurrent illness, including, but not limited to, any of the following:
• •Hypertension; Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Psychiatric illness/social situations that would limit compliance with study requirements
• •No known coagulopathy that increases the risk of bleeding
• •No history of clinically significant hemorrhages
• •Recovered from toxicity of prior therapy
• •At least 3 months since prior radiation therapy, including cranial radiation therapy
• •At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)
• •At least 3 weeks since prior molecularly-targeted agents
• •At least 4 weeks since prior major surgery
• •No more than 2 prior chemotherapy regimens or antineoplastic drugs
• •More than 30 days since prior participation in an investigational trial
• •At least 2 weeks since prior enzyme-inducing antiepileptic drugs (EIAEDs)
• •No concurrent EIAEDs; Concurrent non-EIAEDs allowed
• •No concurrent combination antiretroviral therapy for HIV-positive patients
• •No other concurrent investigational agents
• •No concurrent vascular endothelial growth factor inhibitors:
• •Prior thalidomide or lenolidomide allowed
• •No concurrent anticoagulants (e.g., warfarin) or antiplatelet agents including aspirin
• •No other concurrent anticancer agents or therapies
• •No concurrent grapefruit juice
• •WBC \>= 3,000/mm3
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Absolute neutrophil count \>= 1,500/mm3